These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18034655)

  • 1. Epitope-based vaccine against influenza.
    Ben-Yedidia T; Arnon R
    Expert Rev Vaccines; 2007 Dec; 6(6):939-48. PubMed ID: 18034655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A universal epitope-based influenza vaccine and its efficacy against H5N1.
    Adar Y; Singer Y; Levi R; Tzehoval E; Perk S; Banet-Noach C; Nagar S; Arnon R; Ben-Yedidia T
    Vaccine; 2009 Mar; 27(15):2099-107. PubMed ID: 19356612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influenza virus vaccines].
    Schell KR
    Schweiz Med Wochenschr; 1980 Apr; 110(14):510-22. PubMed ID: 6154970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection.
    Ansaldi F; Canepa P; Parodi V; Bacilieri S; Orsi A; Compagnino F; Icardi G; Durando P
    Vaccine; 2009 May; 27(25-26):3345-8. PubMed ID: 19200846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
    Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
    Vaccine; 2009 Sep; 27(40):5530-7. PubMed ID: 19607950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards an epitope-based human vaccine for influenza.
    Ben-Yedidia T; Arnon R
    Hum Vaccin; 2005; 1(3):95-101. PubMed ID: 17012851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of a sequence-based antigenic distance measure to indicate equine influenza vaccine strain efficacy.
    Daly JM; Elton D
    Vaccine; 2013 Dec; 31(51):6043-5. PubMed ID: 23831320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pandemic preparedness: toward a universal influenza vaccine.
    Roose K; Fiers W; Saelens X
    Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deceptive imprinting and immune refocusing in vaccine design.
    Tobin GJ; Trujillo JD; Bushnell RV; Lin G; Chaudhuri AR; Long J; Barrera J; Pena L; Grubman MJ; Nara PL
    Vaccine; 2008 Nov; 26(49):6189-99. PubMed ID: 18852005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness.
    Ndifon W; Dushoff J; Levin SA
    Vaccine; 2009 Apr; 27(18):2447-52. PubMed ID: 19368786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.
    Goodman AG; Heinen PP; Guerra S; Vijayan A; Sorzano CO; Gomez CE; Esteban M
    PLoS One; 2011; 6(10):e25938. PubMed ID: 21998725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.